Importance: AGN-190584 (Allergan, an AbbVie company) is an optimized topical formulation of pilocarpine hydrochloride, 1.25%, designed for managing presbyopia and enhanced with a proprietary vehicle. Objective: To evaluate the efficacy and safety of pilocarpine hydrochloride, 1.25%, in individuals with presbyopia. Design, Setting, and Participants: This vehicle-controlled, participant- and investigator-masked, randomized, phase 3 clinical study, GEMINI 1, enrolled individuals with presbyopia, aged 40 to 55 years, at 36 sites in the United States from December 21, 2018, to October 31, 2019. Analysis took place between February 2020 and December 2021. Interventions: AGN-190584 or the AGN-190584 formulation vehicle was administered bilaterally, once daily for 30 days. Main Outcomes and Measures: The proportion of participants with improvement of 3 or more lines in mesopic, high-contrast, binocular distance-corrected near visual acuity (DCNVA) at hours 3 and 6 on day 30 were the primary and key secondary efficacy end points, respectively. Safety measures included adverse events. Results: of 323 participants who were randomized, 235 (72.8%) were female and 292 (90.4%) were White. The mean (SD) age was 49.6 (3.5) years, and the baseline mean (SD) mesopic DCNVA was 29.2 (6.3) letters. A total of 163 individuals were randomized to AGN-190584 and 160 were randomized to vehicle. GEMINI 1 met its primary and key secondary efficacy end points. On day 30, hour 3, the percentage of participants with improvement of 3 or more lines in mesopic DCNVA was 30.7% (50 of 163) in the AGN-190584 group and 8.1% (13 of 160) in the vehicle group (difference, 22.5% [95% CI, 14.3%-30.8%]; adjusted P
CITATION STYLE
Waring, G. O., Price, F. W., Wirta, D., McCabe, C., Moshirfar, M., Guo, Q., … Robinson, M. R. (2022). Safety and Efficacy of AGN-190584 in Individuals With Presbyopia. JAMA Ophthalmology, 140(4), 363. https://doi.org/10.1001/jamaophthalmol.2022.0059
Mendeley helps you to discover research relevant for your work.